The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Open accessAbstract
Purpose: Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial and preclinical PC models. Patients and Methods: Patients with PC not amenable to curative therapy who had received no prior therapy for metastatic disease and had Karnofsky performance score ≥ 80 were enrolled. Patients were randomly assigned in a one-to-one ratio to GV or GP. The primary end point was progression-free-survival (PFS). Exploratory correlative studies included serial SHH serum levels and contrast perfusion computed tomography imaging. To further investigate putative biologic mechanisms of SMO inhibition, two autochthonous pancreatic cancer models (Kras G12D; p16/p19 fl/fl; Pdx1-Cre and Kras G12D; p53 R270H/wt; Pdx1-Cre) were studied. Results: No safety issues were identified in the phase Ib portion (n = 7), and the phase II study enrolled 106 evaluable patients (n = 53 in each arm). Median PFS was 4.0 and 2.5 months for GV and GP arms, respectively (95% CI, 2.5 to 5.3 and 1.9 to 3.8, respectively; adjusted hazard ratio, 0.81; 95% CI, 0.54 to 1.21; P = .30). Median overall survival (OS) was 6.9 and 6.1 months for GV and GP arms, respectively (95% CI, 5.8 to 8.0 and 5.0 to 8.0, respectively; adjusted hazard ratio, 1.04; 95% CI, 0.69 to 1.58; P = .84). Response rates were not significantly different. There were no significant associations between correlative markers and overall response rate, PFS, or OS. Preclinical trials revealed no significant differences with vismodegib in drug delivery, tumor growth rate, or OS in either model. Conclusion: The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many of the recent promising clinical signals in PDAC have arisen through rigorous preclinical analyses in syngeneic and autochthonous models that predated the trial and informed its design288.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [288]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y., Gysin, S., Castillo, C. F. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,479
Flagged first, then by citations
1 of the 55 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Abe H, 2005, Radiat Med, 23, 364
- Jesus-Acosta A, 2014, J Clin Oncol, 32
Cited by
Sorted by citations
Items 401–500 of 560
Diab, M., & El‐Rayes, B. F. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.60 · Cited by 10
Signalling in pancreatic cancer: from pathways to therapy
Zhou, K., Liu, Y., Yuan, S., Zhou, Z., Ji, P., Huang, Q., Wen, F., & Li, Q. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2274806 · Cited by 8
Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Chaudhuri, T. R., Lin, Q., Stachowiak, E. K., Rosario, S. R., Spernyak, J. A., Ma, W. W., Stachowiak, M. K., Greene, M. K., Quinn, G. P., McDade, S. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0131 · Cited by 9
Wei, D., Yuan, L., Xu, X., Wu, C., Huang, Y., Zhang, J., Zhang, J., Jing, T., Liu, Y., & Wang, B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217284 · Cited by 10
Mosoh, D. A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136201 · Cited by 10
Parkin, A., Man, J., Chou, A. S. Y., Nagrial, A. M., Samra, J. S., Gill, A. J., Timpson, P., & Pajic, M. (2018) · Diseases · doi:10.3390/diseases6040103 · Cited by 8
Verdaguer, H., Arroyo, A., & Macarulla, T. M. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0609-7 · Cited by 8
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Aderonke, A. B., Ibrahim, R. B., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184624 · Cited by 8
Mejia, I., Bodapati, S., Chen, K. T., & Díaz, B. (2020) · Biomedicines · doi:10.3390/biomedicines8100401 · Cited by 9
Hydrogel models of pancreatic adenocarcinoma to study cell mechanosensing
Walker, M., & Morton, J. (2024) · Biophysical Reviews · doi:10.1007/s12551-024-01265-8 · Cited by 10
Hao, W., Yan, A., Guo, X., Chen, Z., Chen, N., Li, H., Wu, F., Sun, P., Zhao, Y., Zhao, G., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114199 · Cited by 7
Ferroptosis: The dawn of reversing drug resistance in digestive cancers
Chen, W., Han, L., Wang, J., & Song, L. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101873 · Cited by 8
Abrams, S. L., Akula, S. M., Martelli, A. M., Cocco, L., Ratti, S., Libra, M., Candido, S., Montalto, G., Cervello, M., Gizak, A., et al. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100780 · Cited by 7
Obaid, G., Eroy, M., Zhao, J., Bano, S., Mino-Kenudson, M. A., & Hasan, T. G. (2023) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2023.112811 · Cited by 7
Hill, A., & Chung, V. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_6 · Cited by 7
Haram, M., Hansen, R., Myhre, O. F., Solberg, S., Amini, N., Angelsen, B. A., Davies, C. D. L., & Hofsli, E. (2025) · WFUMB Ultrasound Open · doi:10.1016/j.wfumbo.2025.100080 · Cited by 6
RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis
Wang, Y., Yang, Q., Lin, F., Song, X., Yang, G., Wen, D., Yang, Y., Wu, B., Meng, Y., Zhang, N., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw9519 · Cited by 6
Easty, D. J., McDermott, R., Murphy, A. G., Grogan, L., Morris, P. G., Breathnach, O. S., Egan, K., Toomey, S., Horgan, A. M., Power, D. G., et al. (2026) · BMC Cancer · doi:10.1186/s12885-025-14512-2 · Cited by 6
The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment
Wang, X., Li, S., Xue, Y., Liang, X., Ma, X., Zhang, K., & Wang, Y. (2026) · Research · doi:10.34133/research.1183 · Cited by 7
Self-citationDesmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma
Ghanwatkar, Y., Ramanathan, R., & Mahato, R. I. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218618 · Cited by 6
Advances in MUC1 resistance to chemotherapy in pancreatic cancer
Yao, Y., & Fan, D. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2282839 · Cited by 6
Santerre, J. P., Yang, Y., Du, Z., Wang, W., & Zhang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492323 · Cited by 7
Schleinhege, R., Neumann, I., Oeckinghaus, A., Schwab, A., & Pethő, Z. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.12.004 · Cited by 6
Quémerais, C., Jean, C., Brunel, A., Decaup, E., Labrousse, G., Audureau, H., Raffenne, J., Belhabib, I., Cros, J. F., Perraud, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217538 · Cited by 7
START: single‐to‐double arm transition design for phase II clinical trials
Shi, H., Zhang, T., & Yin, G. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2005 · Cited by 6
Sahin, I., Türen, S., Santapuram, P. R., & Şahin, İ. H. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.48 · Cited by 6
Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer
Zhang, K., Chen, Y., Zhu, J., Ge, X., Wu, J., Xu, P., & Yao, J. J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1213136 · Cited by 6
Self-citationAguirre, G. A., Goulart, M. R., Bank, B. P. T., Dalli, J., & Kocher, H. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248547 · Cited by 7
Drug development and clinical trial design in pancreatico-biliary malignancies
Harrington, J., Carter, L., Basu, B., & Cook, N. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.01.003 · Cited by 6
Sinai-Livne, T., Pasmanik‐Chor, M., Cohen, Z., Tsarfaty, I., Werner, H., & Berger, R. (2020) · Oncotarget · doi:10.18632/oncotarget.27566 · Cited by 6
Brunel, A., Samain, R., Neuzillet, C., & Bousquet, C. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.06.09 · Cited by 5
Heid, I., Trajkovic‐Arsic, M., Lohöfer, F. K., Kaissis, G. A., Harder, F. N., Mayer, M., Topping, G. J., Jungmann, F., Crone, B., Wildgruber, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05930-6 · Cited by 5
Xiong, B., Liu, W., Liu, Y., Chen, T., Lin, A., Song, J., Qu, L., Luo, P., Jiang, A., & Wang, L. (2024) · Biomedicines · doi:10.3390/biomedicines12102171 · Cited by 6
Yang, X., Luo, W., Wang, Y., Du, Y., & Yu, R. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070937 · Cited by 7
Tsang, E. S., & Tempero, M. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.22 · Cited by 5
Chang, Y. H., Tam, H.-L., Lu, M.-C., & Huang, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254011 · Cited by 5
Navarro-Serer, B., & Wood, L. D. (2022) · Pancreas · doi:10.1097/mpa.0000000000002084 · Cited by 5
Hung, J. S.-C., Perez, S. M., Dasa, S. S. K., Hall, S. P., Heckert, D. B., Murphy, B. P., Crawford, H. C., Kelly, K. A., & Brinton, L. T. (2023) · Pharmaceuticals · doi:10.3390/ph16030389 · Cited by 6
Wang, Q., Zhao, Y., Wang, F., & Tan, G. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1111816 · Cited by 5
Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J., & Choi, W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_14 · Cited by 5
Shi, H., & Yin, G. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280215625681 · Cited by 5
Macropinocytosis controls metabolic stress-driven CAF subtype identity in pancreatic cancerPreprint
Zhang, Y., Li, L., Maganti, S., Hope, J. L., Galapate, C. M., Carrette, F., Duong‐Polk, K., Bagchi, A., Scott, D. A., Lowy, A. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.625709 · Cited by 5
Maru, S. Y., Wetzel, M., Mitchell, J. T., Groß, N., Andaloori, L., Howe, K., Kartalia, E., Mo, G., Leatherman, J. M., Ho, W. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.27.645833 · Cited by 4
Ge, F., Zhu, H., Liu, X., Li, Y., Guo, R., Zeng, C., Yuan, T., Yang, L., Dong, X., Wu, Y., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116476 · Cited by 4
Shen, Y., Sun, Y., Li, X., Wang, Y., Huang, T., Li, T., Zhu, Y.-Z., Hu, L., & Xu, C. S. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2025.189 · Cited by 5
Li, H., Wang, M., Han, S., Yang, F., Wang, Y., Jin, G., & Sun, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116961 · Cited by 4
Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know
Alkeraye (2022) · Cutis · doi:10.12788/cutis.0601 · Cited by 4
PPAR/PDK4 pathway is involved in the anticancer effects of cGMP in pancreatic cancer
Yamashita, M., Kumazoe, M., Onda, H., Hiroi, S., Shimada, Y., Fujimura, Y., & Tachibana, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.06.043 · Cited by 4
Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach
Pea, A., Liang Cheng, C., & Luchini, C. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1604135 · Cited by 4
Yonemura, H., Kuwatani, M., Nakajima, K., Masamune, A., Ogawa, M., & Sakamoto, N. (2025) · Cancers · doi:10.3390/cancers17091584 · Cited by 3
Abdi, U., Zhang, M., & Al-Jamal, W. T. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00161g · Cited by 3
Capurso, G., Garajová, I., Neuzillet, C., Leta, L. C., Dusetti, N., & Reni, M. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.020 · Cited by 3
Heilijgers, F., Bakker, M.-C., van Hest, B., Franken, I. A., Speetjens, F. M., Peeters, K. C. M. J., Roodhart, J. M. L., & Mesker, W. E. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01220-5 · Cited by 4
Tomasich, E., Mühlbacher, J., Wöran, K., Hatziioannou, T., Herac, M., Kleinberger, M., Berger, J. M., Dibon, L. K., Berchtold, L., Heller, G., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.05.005 · Cited by 4
Knockdown of TGF-β in Pancreatic Cancer Helps Ameliorate Gemcitabine Resistance
Wang, X., Su, W., Qin, C., Gao, R., Shao, S., Xu, X., Zhang, Z., & Gao, J. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907269 · Cited by 3
Self-citationBangbo, Z., Qin, C., Zeru, L., Wang, Y., 杨晓莹, Li, T., Yu-Pei, Z., Wang, W., & Yu-Pei, Z. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05599-8 · Cited by 3
Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma
Kamgar, M., Chakrabarti, S., Shreenivas, A. V., & George, B. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.004 · Cited by 3
Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management
Akce, M., & El‐Rayes, B. F. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.27 · Cited by 3
Hedgehog Signaling Plays a Dual Role in Pancreatic Carcinogenesis
Hogenson, T. L., Olson, R., & Fernández-Zapico, M. E. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_76 · Cited by 3
BAHAT, A. V., Bar-David, S., Brooks, A., Aizic, A., Greenberg, O., Wolf, I., Klausner, J. M., Lahat, G., & Nizri, E. (2020) · Anticancer Research · doi:10.21873/anticanres.14667 · Cited by 3
Datta, J., Dai, X., Bianchi, A., Silva, I. D. C., Mehra, S., Garrido, V. T., Lamichhane, P., Singh, S. P., Zhou, Z., Dosch, A. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.07.434236 · Cited by 3
Mason, J. E., Cumming, J., Eriksson, A., Binder, C., Dongre, M., Patthey, C., Espona‐Fiedler, M., Chorell, E., & Öhlund, D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.11.483991 · Cited by 3
Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancerPreprint
Costa, D. B. V., Francescone, R., Franco‐Barraza, J., Luong, T., Graves, M., de Aquino, A. M., Steele, N. G., Gardiner, J. C., dos Santos, S. A. A., Ogier, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.15.594354 · Cited by 3
Deng, Z., Yu, H., Wu, N., Wang, Q., Wang, J., Yue, Y., Geng, L., & Zhang, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1600349 · Cited by 2
Franco‐Barraza, J., Dmitrieva, M., Luong, T., Egleston, B. L., Raghavan, K. S., Wong, J. K., Costa, D. B. V., Francescone, R. A., III, Gardiner, J. C., Handorf, E. A., et al. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100902 · Cited by 3
Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy
Hu, X., Wang, Z., Zhu, Y., Ma, P., Zheng, R., Zhi, X., Yan, H., Xiao, T., Tian, J., & Wang, Q. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114745 · Cited by 2
Xu, J., Chu, T., Liu, Z., (281351), H. L., Duan, K., Liu, X., Yang, H., Lou, F., Liu, H., Chi, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102275 · Cited by 2
Stukan, А. I., Алексеевич, М. Р., Porkhanov, V. A., Барышев, А. Г., Гилевич, И. В., & Bodnya, V. N. (2021) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20211004166 · Cited by 3
Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation
Liu, T., Cheng, S., Xu, Q., & Wang, Z. P. (2022) · Medicina · doi:10.3390/medicina58091298 · Cited by 2
Kapeni, C., O’Brien, L. M., Sabirova, D., Cast, O. M., Carbonaro, V., Clark-Leonard, S., Machel, A. C., Beke, F., McDonald, S., Fife, K. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adr3127 · Cited by 2
Zhou, Y., Wang, Y., Cheng, J.-T., Zhang, Y., Cai, W.-Q., Han, Z.-W., Wang, M., Huang, Q., Peng, X., & Xin, H. (2021) · Yangtze Medicine · doi:10.4236/ym.2021.52015 · Cited by 2
Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer
Tang, M., Chen, J., Goldstein, D., Links, M. J., Lord, S. J., Marschner, I. C., Simes, R. J., & Lee, C. K. (2019) · Pancreas · doi:10.1097/mpa.0000000000001429 · Cited by 2
Immuno-Oncology in Pancreatic Cancer
Jamieson, N. B., & Steele, C. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_20 · Cited by 2
Nezami, M. A., Hager, S. J., & Shirazi, R. (2023) · Journal of Cancer Therapy · doi:10.4236/jct.2023.149033 · Cited by 1
Chen, C., Feng, Y., Ko, F. C. F., Lam, S. K., Yan, S., & Ho, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1597585 · Cited by 1
Zhan, S., & Feng, P.-F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1596658 · Cited by 1
Digital quantification of stroma percentage enhances prognostic stratification in pancreatic cancer
Bengtsson, A., Andersson, R. E., Andersson, B., & Ansari, D. (2026) · Surgery Open Science · doi:10.1016/j.sopen.2026.01.002 · Cited by 2
Colony-stimulating factor-2 triggers NNMT-dependent myofibroblast activation in head and neck cancer
Li, R., Yang, X., Li, Y., Duan, Y., Wu, Y., Zhao, H., & Shang, Z. (2026) · Oncogene · doi:10.1038/s41388-026-03749-1 · Cited by 1
Girolimetti, G., Bramato, G., Fiore, A., Romanò, R., Guerra, F., Bucci, C., & Basset, A. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105309 · Cited by 1
Truong, H. T. T., Kwon, W., Woo, H. J., Kim, M. S., Trần, N. Q., & Joung, J. Y. (2026) · Cancers · doi:10.3390/cancers18101600 · Cited by 1
The role of cancer-associated fibroblasts in various cancer drug resistance
Dang, F., Na, J., Xiao, L., Tian, X., Shao, J., Zhong, L., & Zhao, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218584 · Cited by 1
Riccò, B., Grisendi, G., Monaco, A. L., Giuggioli, D., Clini, E. M., & Dominici, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119626 · Cited by 1
Cao, Y., (51274), X. L., Gong, W., Tan, J., Shen, J., & Zhou, X. (2026) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2026.104503 · Cited by 1
Eissa, I. R., Cohen, S., Boland, G. M., Sharova, T. Y., & Tanabe, K. K. (2026) · iScience · doi:10.1016/j.isci.2026.116500 · Cited by 1
Ma, H., Lu, H., Zhang, Z., Wang, J., Zhao, Q., Ding, Y., Wang, X., Zhang, W., Li, N., & Wang, S. (2026) · Discover Oncology · doi:10.1007/s12672-026-05562-4 · Cited by 1
Self-citationMirzabeigi, Y., Youssef, J., Gonzalez, J. S., Martinez, T., Avellan, R., Wong, A. G., Perez, M., Carvajal, L. L., Abou-Kheir, W. G., & Bahmad, H. F. (2026) · Cancers · doi:10.3390/cancers18142358 · Cited by 1
Precision targeting of stromal states in pancreatic cancer: a clinical perspective
Wolters, A., Bijlsma, M. F., & Prakash, J. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.07.003 · Cited by 1
Selecting the Optimal Parameters for Sonoporation of Pancreatic Cancer in a Pre-Clinical Model
Schultz, C. W., Torkzaban, M., Wallace, K. D., Eisenbrey, J. R., Kotopoulis, S., Brody, J. R., Forsberg, F., Liu, J., Dhir, T., Wessner, C. E., et al. (2019) · IEEE International Ultrasonics Symposium · doi:10.1109/ultsym.2019.8925889 · Cited by 1
Efficacy and Safety of PEGPH20 in Pancreatic Cancer: Systematic Review and Meta-analysis
Solipuram, V. K. R., Gopalakrishna, H., Nair, G. B., & Mohan, A. (2021) · Current Cancer Therapy Reviews · doi:10.2174/1573394717666210616152341 · Cited by 1
Development of Novel Therapeutic Response Biomarkers
Elander, N., Aughton, K., & Greenhalf, W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_59 · Cited by 1
Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J., & Choi, W. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_14-2 · Cited by 1
Bayesian single‐to‐double arm transition design using both short‐term and long‐term endpoints
Xu, T., Shi, H., & Lin, R. (2023) · Pharmaceutical Statistics · doi:10.1002/pst.2292 · Cited by 1
Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer
Harwansh, R. K., Hamid, J. A., Wal, P., Deshmukh, R., Patra, P. K., & Gasmi, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128334659241223113743 · Cited by 2
Evolving trends in pancreatic cancer therapeutic development
Bijou, I., & Wang, J. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.09.01 · Cited by 1
Therapeutic Targeting of Stromal Components
Neeße, A. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_11 · Cited by 1
Hedgehog Signaling Plays a Dual Role in Pancreatic Carcinogenesis
Hogenson, T. L., Olson, R., & Fernández-Zapico, M. E. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_76-1 · Cited by 1
Tumor-Antagonizing Fibroblasts Secrete Prolargin as Tumor Suppressor in Hepatocellular CarcinomaPreprint
Chiavarina, B., Ronca, R., Otaka, Y., Sutton, R. B., Rezzola, S., Yokobori, T., Chiodelli, P., Souche, F.-R., Maraver, A., Faa, G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.04.425182 · Cited by 1
Henze, J. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8758 · Cited by 1
Neuzillet, C. (2018) · theses.fr (ABES) · doi:10.70675/71b3d021zb0eaz45a4z95a5zdb254dc5bde0 · Cited by 1
Bittoni, A. (2016) · Università Politecnica delle Marche (Università Politecnica delle Marche)
Metadata
- Authors
- Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., Cohen, D., Wade, J., Sleckman, B., Lenz, H.-J., Stiff, P., Kumar, P., Xu, P., Henderson, L., Takebe, N., Salgia, R., Wang, X., Stadler, W. M., de Sauvage, F. J., & Kindler, H. L.
- Affiliations
- Loyola University Medical Center (US)
- Daniel V.T. Catenacci, Theodore Karrison, James Wallace, Mark Kozloff, Peng Xu, Les Henderson, Ravi Salgia, Walter M. Stadler, Hedy L. Kindler, University of Chicago Medical Center; Patrick Stiff, Loyola University Medical Center, Chicago; Robert Marsh, Northshore University Health System, Evanston; James Wallace, Mark Kozloff, Ingalls Hospital, Harvey; James Wade, Decatur Memorial Hospital, Decatur; Pankaj Kumar, Oncology/Hematology Associates, Peoria, IL; Melissa R. Junttila, Xi Wang, and Frederic J....
- Corresponding author
- Catenacci, Daniel V.T.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-20
- Volume
- 33
- Issue
- 36
- Pages
- 4284-4292
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4678179
- OpenAlex
- W2137357003
- Cited by
- 561
- References
- 55
- Citations by year
- 2026: 40 · 2025: 36 · 2024: 38 · 2023: 47 · 2022: 71 · 2021: 72 · 2020: 67 · 2019: 65 · 2018: 60 · 2017: 41 · 2016: 20 · 2015: 3
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- European Society for Medical Oncology
- National Institutes of Health (UL1TR000430, n01cm62201-16-0-1)
- Genentech
- National Cancer Institute (N01 CM062201, N01 CM-62201)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metastatic pancreatic cancer, gemcitabine, vismodegib, sonic hedgehog pathway, Smoothened inhibition, Hedgehog pathway inhibitors, progression-free survival, overall survival, KRAS G12D, p53, drug safety, combination therapy
- MeSH terms
- Gemcitabine, Adult, Aged, Anilides, Animals, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Pyridines, Signal Transduction, Odds Ratio, Treatment Outcome, Karnofsky Performance Status, Disease-Free Survival, Mice, Kaplan-Meier Estimate, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
